ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
General Health & Fitness
Health & Wellness
Chronic high-dose angiotensin receptor blocker use associated with cancer risk (2022)
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="Biobro" data-source="post: 228277" data-attributes="member: 43789"><p>[URL unfurl="true"]https://www.healio.com/news/cardiology/20220302/chronic-highdose-angiotensin-receptor-blocker-use-associated-with-cancer-risk[/URL]</p><p></p><p>“It already changed my practice,” Sipahi told Healio. “I rarely prescribe an ARB for hypertension now. However, I continue to prescribe the sacubitril/valsartan combination (Entresto, Novartis) in heart failure because of the mortality benefit there.”</p><p></p><p></p><p></p><h2>Risk of cancer with angiotensin-receptor blockers increases with increasing cumulative exposure: Meta-regression analysis of randomized trials</h2><p>[URL unfurl="true"]https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0263461#pone.0263461.ref048[/URL]</p><p></p><p>Conclusion:</p><p></p><p>This analysis shows that risk of cancer and specifically lung cancer increase with increasing cumulative exposure to ARBs. The relationship between cumulative exposure to ARBs and cancer risk explains the heterogeneity in the results of randomized trials, since trials were highly heterogeneous in terms of cumulative exposure. Detailed and impartial analysis of the vast amount of patient-level data of randomized trials that the regulatory agencies already have, including examination of cumulative exposure—risk relationship, can confirm the current findings. Because of the ongoing widespread use of ARBs globally, their potential of excess cancer risk with long-term use has profound implications for patients and prescribing clinicians.</p></blockquote><p></p>
[QUOTE="Biobro, post: 228277, member: 43789"] [URL unfurl="true"]https://www.healio.com/news/cardiology/20220302/chronic-highdose-angiotensin-receptor-blocker-use-associated-with-cancer-risk[/URL] “It already changed my practice,” Sipahi told Healio. “I rarely prescribe an ARB for hypertension now. However, I continue to prescribe the sacubitril/valsartan combination (Entresto, Novartis) in heart failure because of the mortality benefit there.” [HEADING=1]Risk of cancer with angiotensin-receptor blockers increases with increasing cumulative exposure: Meta-regression analysis of randomized trials[/HEADING] [URL unfurl="true"]https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0263461#pone.0263461.ref048[/URL] Conclusion: This analysis shows that risk of cancer and specifically lung cancer increase with increasing cumulative exposure to ARBs. The relationship between cumulative exposure to ARBs and cancer risk explains the heterogeneity in the results of randomized trials, since trials were highly heterogeneous in terms of cumulative exposure. Detailed and impartial analysis of the vast amount of patient-level data of randomized trials that the regulatory agencies already have, including examination of cumulative exposure—risk relationship, can confirm the current findings. Because of the ongoing widespread use of ARBs globally, their potential of excess cancer risk with long-term use has profound implications for patients and prescribing clinicians. [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
General Health & Fitness
Health & Wellness
Chronic high-dose angiotensin receptor blocker use associated with cancer risk (2022)
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top